Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | DRD4 | P21917 | 10/20 | 0.47 |
| ▸ | DRD3 | P35462 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577486 | 0.93 | DRD2 (0.47) | DRD2DRD4DRD3LMNAHPGD | |
| SCHEMBL5715680 | 0.87 | LMNA (0.45) | DRD2DRD4DRD3LMNAHPGD | |
| SCHEMBL5577901 | 0.87 | MT-CO2 (0.50) | DRD3LMNACHRM3SIGMAR1ACKR3 | |
| SCHEMBL5577535 | 0.87 | S1PR1 (0.47) | DRD2DRD4DRD3LMNACCR3 | |
| SCHEMBL5577897 | 0.86 | GAA (0.54) | LMNACHRM3ACKR3 | |
| SCHEMBL5577735 | 0.85 | LMNA (0.46) | LMNAHPGDAPEX1CHRM3CCR3 | |
| SCHEMBL5577605 | 0.83 | LMNA (0.45) | DRD2DRD4DRD3LMNACCR3 | |
| SCHEMBL5577568 | 0.83 | LMNA (0.49) | DRD2DRD4DRD3LMNAHPGD | |
| SCHEMBL5577426 | 0.83 | PDE5A (0.41) | DRD2DRD4DRD3LMNACCR3 | |
| SCHEMBL5577591 | 0.83 | DRD4 (0.42) | DRD2DRD4DRD3CCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | DRD2 4468/4885DRD4 4092/4885DRD3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.